July 2003: Case Study 1

Published Online: Tuesday, July 1, 2003

KC?s grandmother enters the pharmacy excitedly. She approaches the counter and asks to speak with KC, the pharmacist. She tells KC that she heard from the "girls at my bridge game" that a new product is available for the treatment of overactive bladder. The "girls" told her that it was in the form of a patch. She wants to know whether she should ask her physician to write a prescription for her.

KC knows that her grandmother is frustrated by her overactive bladder problems. She is also embarrassed by her need to wear protective undergarments. The only medication covered by her grandmother?s insurance plan is generic oxy-butynin. Unfortunately, her doctor has determined that oxybu-tynin is not an appropriate therapy for her due to her uncontrolled narrow-angle glaucoma. Due to her limited income, she is unable to afford any medications that are not covered by her insurance plan.

If her grandmother?s insurance plan covers this new patch, is this an appropriate alternative for her?

Click Here For The Answer -----------> [-]

Unfortunately, the new patch contains oxybutynin. Although this patch will provide the ease of twice-weekly patch changes and reduced side effects, it should not be used in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma.

Latest Articles
Mylan has announced the US launch of clozapine orally disintegrating tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical’s FazaClo.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about some safeguards pharmacists can implement.
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Latest Issues